Skip to content
Menu

Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $41

Benzinga Newsdesk 4 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $48 to $41.

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $48 to $41.

Read at benzinga.com